Keystone Heart Ltd is a medical device company developing and manufacturing cerebral protection devices to reduce the risk of stroke, neurocognitive decline and dementia caused by brain damage associated with cardiovascular procedures.
Keystone Heart is dedicated to advancing patient care through innovative technology and clinical research. Clinical studies with the TriGuard™ Cerebral Protection Device (TAVR procedures) are currently ongoing in Europe, Canada and Brazil with impending CE Mark.
Keystone Heart collaborates with renowned interventional cardiologists, cardiac surgeons and neurologists.
The Company’s management has extensive experience in the fields of interventional cardiology and medical devices.
Founded in 2004 and headquartered in Israel, Keystone Heart is funded by OrbiMed Advisors LLC and OrbiMed Israel Partners.
The Company (previously known as SMT Research & Development) holds and maintains a comprehensive IP portfolio and is ISO certified.